SEC Form 4 · accession 0001209191-16-156550
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Shawn Tomasello
Officer — Chief Commercial Officer
Period of report
Dec 20, 2016
Accepted (ET)
Dec 22, 2016 · 4:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Dec 20, 2016 | S | 4,901 | $50.86 | D | 49,635 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.
- F2Includes 536 shares acquired under the 2014 Employee Stock Purchase Plan on August 19, 2016.